Clinical trial
Irinotecan in Treating Young Patients With Refractory or Recurrent…
NCT00287976 · Children's Cancer and Leukaemia Group, Other · Unknown status
Key facts
| NCT number | NCT00287976 |
|---|---|
| Title | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma |
| Official title | Irinotecan Single-Drug Treatment For Children With Refractory or Recurrent Hepatoblastoma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 30 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2008 |
| First posted | Feb 7, 2006 |
| Last update posted | Sep 17, 2013 |
| Countries | Ireland, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: